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Background
We have recently reported that the combination of a neu-
tral endopeptidase inhibitor (NEPI; prevents the break-
down of natriuretic peptides) and a phosphodiesterase 5
inhibitor (PDE5-I; prevents the hydrolysis of cyclic GMP),
synergistically prevents pathogenesis in a hypoxia-
induced model of pulmonary hypertension (PH; [1]).
Herein, we have assessed the efficacy of this novel combi-
nation therapy to reverse disease severity in (a) estab-
lished PH and (b) bleomycin-induced pulmonary
fibrosis.
Methods and results
(a) Reversal of existing PH
In this study, the combination therapy (NEPI: ecadotril 60
mg/kg/day; PDE5I: sildenafil 30 mg/kg/day) was initiated
after rats had been exposed to 3 weeks of chronic hypoxia
(10% O2) to induce PH. This intervention resulted in a
less pronounced elevation in right ventricular pressure
(Control: 21.57 ± 3.432 mmHg, Hypoxia: 34.32 ± 3.882
mmHg, Hypoxia + combination therapy: 29.17 ± 1.965
mmHg) and reduced right ventricular hypertrophy (RV/
LV+S ratio; Control: 0.2839 ± 0.01874, Hypoxia: 0.3411 ±
0.03317, Hypoxia + combination therapy: 0.3063 ±
0.01412) compared to untreated animals.
(b) Bleomycin-induced pulmonary fibrosis
Pulmonary hypertension often complicates interstitial
lung disease, where it is associated with higher mortality.
Bleomycin, a peptide antibiotic, causes oxidant-mediated
DNA scission leading to fibrogenic cytokine release and is
a commonly used mouse model of pulmonary fibrosis.
Our data suggest that the NEPI/PDE5-I combination is
effective in ameliorating the rise in right ventricular systo-
lic pressure (RSVP) in response to bleomycin (1 U/kg;
Control: 21.14 ± 4.028 mmHg, bleomycin: 33.84 ± 2.397
mmHg, bleomycin + combination therapy: 25.18 ± 1.902
mmHg; Figure 1).
Conclusion
These data demonstrate that the NEPI/PDE5I combina-
tion is effective in ameliorating disease severity in two
models of PH with disparate aetiologies. First, the combi-
nation is valuable in reversing established (hypoxia-
induced) PH and, second, the dual therapy is capable of
reversing the pulmonary haemodynamic dysfunction in
bleomycin-induced pulmonary fibrosis. Thus, this work
substantiates the therapeutic potential of this novel com-
bination therapy in PH.
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RSVP in control animals (n = 6) and bleomycin-treated ani-mals (n = 6) in the absence and presence of sildenafil (SILD, n = 7), ecad tril (NEPI, n = 8) and combination tre tment (SILD+NEPI, n = 9)Figure 1
RSVP in control animals (n = 6) and bleomycin-
treated animals (n = 6) in the absence and presence 
of sildenafil (SILD, n = 7), ecadotril (NEPI, n = 8) and 
combination treatment (SILD+NEPI, n = 9). *P < 0.05.Page 2 of 2
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